TABLE 3.
Prevalence of antibodies to HPgV-2 in HCV-infected, HIV-infected, HBV-infected, and volunteer control samples
| Reference group | No. HPgV-2 antibody positive | Antibody prevalence (% [95% CI]) | P valuea | No. (%) positive by supplemental testing/total no.b |
||||
|---|---|---|---|---|---|---|---|---|
| RNA | NS4AB (RNA) | Peptide (RNA) | NS4AB and peptide (RNA) | NS4AB, peptide, or RNA | ||||
| HCV infectedc (n = 726) | 24 | 3.31 (2.13–4.88) | NA | 11 | 11 (7) | 14 (7) | 11 (7) | 18/24 (75.00) |
| HCV infected (RNA negative/antibody positive) (n = 299) | 3 | 1.00 (0.21–2.90) | 0.0502 | 1 | 1 (1) | 2 (1) | 1 (1) | 2/3 (66.67) |
| HIV (n = 434) | 0 | 0.00 (0.00–0.85) | 0.0001 | 0 | 0 (0) | 0 (0) | 0 (0) | 0/0 (0.00) |
| HBV (n = 456) | 3 | 0.66 0.14–1.91 | 0.0023 | 0 | 2 (0) | 0 (0) | 0 (0) | 2/3 (66.67) |
| Volunteer donors (n = 416) | 1 | 0.24 (<0.01–1.33) | 0.0002 | 0 | 0 (0) | 1 (0) | 0 (0) | 0/0 (0.00) |
| Total non-HCV (n = 1,306) | 4 | 0.31 (0.08–0.78) | 0.0001 | 0 | 2 (0) | 1 (0) | 0 (0) | 2/4 (50.00) |
| Total (n = 2,331) | 31 | 1.33 (0.91–1.88) | NA | 12 | 14 (8) | 17 (7) | 12 (8) | 22/31 (70.97) |
a
P values were calculated using Fisher's exact test, comparing the HCV group with the HIV, HBV, and volunteer control groups. NA, not applicable.
b
Supplemental testing was performed for HPgV-2 RNA, anti-NS4AB, or peptide reactivity.
c
The sample set includes only HCV RNA-positive/antibody-positive samples; it does not include the previously identified samples UC0125.US and ABT0239AN.US (HCV RNA positive only). The longitudinal bleed samples ABT0035P.US and ABT0041P.US were counted as 2 samples in the analysis.